Ian Wendt

Chief Commercial Officer @Jaguar Health

Full P&L responsibility for US assets in Human Health and Animal Health divisions. Provided board-level executive leadership regarding short and long-term strategic planning and execution. Key Achievements • Successfully turned around an inline retail channel asset to specialty pharmacy distribution and implemented a suite of patient support programs that improved medication access. GTN increased from ~30% to ~75% over a two-year transition period. Most recent year-over-year net sales increased by 112% for a 10-year-old drug with flat spending. Gross profit increased by 8x from 2019 to 2022. • Achieved operating profitability in 2021 for the commercial team for the first time in the company’s history. • Led launch planning and market-shaping activities for a chloride ion channel modulator in the Oncology supportive care market. • Launched a first-in-class chloride ion channel modulator in the veterinary Oncology market. • Supported a variety of BD efforts that resulted in two ex-US licensing deals for commercial assets.